China SXT Pharmaceuticals Overview
China SXT Pharmaceuticals (SXTC) has a P/E ratio of -0.01, below the Consumer Discretionary sector average of 47.18.
Get informed when a big investor buys or sells
+ Follow-0.01
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for SXTC is -0.01. That is below the Consumer Discretionary sector average of 47.18. Investors often review this figure alongside China SXT Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Consumer Discretionary companies, SXTC currently prints -0.01 for P/E ratio, while the sector average sits near 47.18. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at China SXT Pharmaceuticals's growth, margins, and balance sheet.
A P/E ratio of -0.01 for China SXT Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (47.18) and with SXTC's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting SXTC's P/E ratio (-0.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack China SXT Pharmaceuticals's P/E ratio against similar Consumer Discretionary names. You can also browse sector and industry screens on Stockcircle for a broader set of Consumer Discretionary companies and their key multiples and fundamentals.
